Targets and modern strategy of therapy for different groups of patients with type 2 diabetes mellitus


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors is one of the most promising groups of hypoglycemic drugs (HGDs) used for the treatment of type 2 diabetes mellitus. In recent years, DPP-4 inhibitors have become widespread due to a unique mechanism of action, high efficiency and safety, availability and ease of use. One of the most promising combinations of HGDs is the combination of DPP-4 inhibitors with metformin, which affects virtually all stages of progression of type 2 diabetes mellitus. First of all, it concerns such a DPP-4 inhibitor as vildagliptin (Galvus), which together with metformin is a part of the fixed combination Galvus Met. The selective and reversible inhibition of the DPP-4 enzyme against the background of therapy with vildagliptin results in an increase in the half-life of the endogenously secreted glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1, increasing the possibility of glucose-dependent insulin secretion by ß cells and exerting pleiotropic extra-pancreatic effects, and metformin remains the drug of choice for correction insulin resistance.

Full Text

Restricted Access

About the authors

Tatiana Yu. Demidova

N.I. Pirogov Russian National Research Medical University

Email: t.y.demidova@gmail.com
MD, professor, head of the Department of endocrinology

Daria V. Skuridina

N.I. Pirogov Russian National Research Medical University

Email: shurpesha@mail.ru
assistant of the Department of endocrinology

Yaroslava V. Pugovkina

Russian Medical Academy of Continuous Professional Education

postgraduate student of the Department of endocrinology and diabetology

References

  1. International Diabetes Federation. IDF Diabetes Atlas Seventh Edition http://www.diabetesatlas.org.
  2. DeFronzo R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-95.
  3. Schwartz S.S., Epstein S., Corkey B.E., Grant S.F.A., Gavin J.R. 3rd, Aguilar R.B. The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centric classification schema. Diabetes Care. 2016;39:179-86.
  4. Аметов А.С. Патофизиологический подход как основа выбора стратегии успешного лечения сахарного диабета 2 типа. Фарматека. 2017;5:28-35 [Ametov A.S. Pathophysiological approach as a basis for the selection of strategy for the success treatment of type 2 diabetes mellitus. Pharmateca. 2017;5:28-35 (in Russ.)]
  5. De Fronzo R.A., Eldor R., Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36 (Suppl. 2):127-38.
  6. Del Prato S., Foley J.E., Kothny W., Kozlovski P., Stumvoll M., Paldanius P.M., Matthews D.R. Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. Diabet Med. 2014;31(10):1178-84.
  7. Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом, 8-й выпуск. Москва. 2017. [Dedov I.I., Shestakova M.V. Algorithms of specialized medical care for patients with diabetes mellitus, 8th edition. Moscow. 2017 (in Russ.)]
  8. Ahrén B., Foley J.E. Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia. 2016;59:907-17.
  9. Bosi E., Dotta F., Jia Y., Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes. Obes. Metab. 2009;1 1(5):506-1 5.
  10. Bosi E. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890-5.
  11. Matthews D.R., Dejager S., Ahren B., Fonseca V., Ferrannini E., Couturier A., Foley J.E., Zinman B. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes. Obes. Metab. 2010;12(9):780-9.
  12. Ferrannini E., Fonseca V., Zinman B., Matthews D., Ahrén B., Byiers S., Shao Q., Dejager S. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes. Metab. 2009;11(2):157-66.
  13. Ahrén B., Foley J.E., Ferrannini E. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2010;33:730-2.
  14. Rombopoulos G., Hatzikou M., Athanasiadis A., Elisaf M. Treatment compliance with fixed-dose combination of vildagliptin/ metformin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: a 24-week observational study. Int. J. Endocrinol. 2015;201 5:251485.
  15. Frontoni S., Di Bartolo P., Avogaro A., Bosi E., Paolisso G., Ceriello A. Glucose variability: An emerging target for the treatment of diabetes mellitus. Diabetes Res. Clin. Pract. 2013;102:86-95.
  16. Ceriello А., Ihnat M.A. «Glycaemic variability»: a new therapeutic challenge in diabetes and the critical care setting. Diabetic Med. 2010;27:862-7.
  17. Zenari L., Marangoni A. What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2013;15(Suppl. 2):17-25.
  18. Nalysnyk L., Hernandez-Medina М., Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus:evidence from a systematic review of the literature. Diabetes Obes. Metab. 2010;12(4):288-98.
  19. Sourij H., Saely C.H., Schmid F., Zweiker R., Marte T., Wascher T.C., Drexel H. Post-challenge hyperglycaemia is strongly associated with future macrovascular events and total mortality in angiographied coronary patients. Eur. Heart J. 2010;31(13):1583-90.
  20. Su G., Mi S., Tao H., Li Z., Yang H., Zheng H. et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc. Diabetol. 2011;10:1119-86.
  21. Hsu C.R., Chen Y.T., Sheu W.H. Glycemic variability and diabetes retinopathy: a missing link. J Diabetes Complications. 2015;29:302-6.
  22. Jin S.M., Kim T.H., Oh S., Baek J., Joung J.Y., Park S.M., Cho Y.Y., Sohn S.Y., Hur K.Y., Lee M.S., Lee M.K., Kim J.H. Association between the extent of urinary albumin excretion and glycaemic variability indices measured by continuous glucose monitoring. Diabet Med. 2015;32:274-9.
  23. He Y.L., Foteinos G., Neelakantham S., Mattapalli D., Kulmatycki K., Forst T., Taylor A. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring. Diabetes Obes. Metab. 2013;15(12):1111-9.
  24. Marfella R., Barbieri M., Grella G., Rizzo M.R., Nicoletti G.F., Paolisso G. Effects of vildagliptin twice daily versus sitagliptin once daily on 24-hour acute glucose fluctuations. J. Diabetes Complications. 2010;24:79-83.
  25. Neumiller J.J. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J. Am. Pharm. Assoc. 2009;49(Suppl. 1):S16-29.
  26. Rizzo M.R., Barbieri M., Marfella R., Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes. role of dipeptidyl peptidase-iv inhibition. Diabetes Care. 2012;35(10):2076-82.
  27. Lukashevich V., Del Prato S. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes. Metab. 2014;16:403-9.
  28. Fonseca V., Schweizer A., Albrecht D., Baron M.A., Chang I., Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148-55.
  29. Ved P., Shah S. Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus. Indian J. Endocrinol. Metab. 2012;16(Suppl. 1):S110-3.
  30. Green J.B., Bethel M.A., Armstrong P.W., Buse J.B., Engel S.S., Garg J., Josse R., Kaufman K.D., Koglin J., Korn S., Lachin J.M., McGuire D.K., Pencina M.J., Standl E., Stein P.P., Suryawanshi S., Van de Werf F., Peterson E.D., Holman R.R.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2015;373(3):232-42.
  31. White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., Perez A.T., Fleck P.R., Mehta C.R., Kupfer S., Wilson C., Cushman W.C., Zannad F.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes N. Engl. J. Med. 2013;369(2013):1327-35.
  32. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., Ohman P., Frederich R., Wiviott S.D., Hoffman E.B., Cavender M.A., Udell J.A., Desai N.R., Mosenzon O., McGuire D.K., Ray K.K., Leiter L.A., Raz I.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013;369:1317-26.
  33. McInnes G., Evans M., Del Prato S., Stumvoll M., Schweizer A., Lukashevich V., Shao Q., Kothny W. Cardiovascular and heart failure safety profile of vildagliptin:a meta-analysis of 17 000 patients. Diabetes Obes. Metab. 2015;17(11):1085-92.
  34. Eriksson J.W., Bodegard J., Nathanson D., Thuresson M., Nyström T., Norhammar A. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Res. Clin. Pract. 2016;117:39-47.
  35. Rathmann W., Kostev K., Gruenberger J.B., Dworak M., Bader G., Giani G. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes. Metab. 2013;15(1):55-61.
  36. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977-86.
  37. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
  38. Patel A., MacMahon S., Chalmers J. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008;358:2560-72.
  39. Трубицына Н.П., Северина А.С., Шамхалова М.Ш., Шестакова М.В. Современные возможности сахароснижающей терапии при сахарном диабете 2 типа и хронической болезни почек. Проблемы эндокринологии. 2015;6:36-43. [Trubitsyna N.P., Severina A.S., Shamkhalova M.Sh., Shestakova M.V. Modern possibilities of hypoglycemic therapy of type 2 diabetes mellitus and chronic kidney disease. Problems of endocrinology. 2015;6:36-43 (in Russ.)]
  40. Lukashevich V., Schweizer A., Shao Q., Groop P.H., Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes. Metab. 2011;13:947-54.
  41. Schweizer A., Dejager S. Experience with vildagliptin in patients s75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther. 2013;4:257-67.
  42. Strain W.D., Lukashevich V., Kothny W., Hoellinger M.J., Paldanius P.M. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebocontrolled study. Lancet. 2013;382(9890):409-16.
  43. Mathieu C., Barnett A.H., Brath H., Conget I., de Castro J.J., Göke R., Márquez Rodriguez E., Nilsson M., Pagkalos E., Penfornis A., Schaper N.C., Wangnoo S.K., Kothny W., Baderet G. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int. J. Clin. Pract. 2013;67(10):947-56.
  44. Ahrén B., Mathieu C., Bader G., Schweizer A., Foley J.E. Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia. 2014;57:1304-7.
  45. Blüher M., Kurz I., Dannenmaier S., Dworak M. Efficacy and safety of vildagliptin in clinical practice: results of the PROVIL-study. World J. Diabetes. 2012;3(9):161-9.
  46. Rosales R., Abou Jaoude E., Al-Arouj M., Fawwad A., Orabi A., Shah P., Di Tommaso S., Vaz J., Latif Z.A. Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study. Diabetes Obes. Metab. 2015;17:603-7.
  47. Blüher M., Kurz I., Dannenmaier S., Dworak M. Pill burden in patients with type 2 diabetes in Germany: subanalysis from the prospective, noninterventional PROVIL Study. Clin. Diabetes. 2015;33(2):55-61.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies